Siemens Healthineers (ETR:SHL) Trading 1.5% Higher - What's Next?

Key Points

• Shares of Siemens Healthineers traded up 1.5% on Monday, hitting an intraday high of €39.46 and last trading at €38.91 on volume of 1,488,176 shares (previous close €38.35).
• The company has a market capitalization of $43.90 billion, with a PE ratio of 22.62, PEG of 1.16, beta 0.80, and a relatively high debt-to-equity ratio of 82.28 alongside current and quick ratios of 1.04 and 0.71.
• Siemens Healthineers develops and sells diagnostic and therapeutic products through four main segments: Imaging, Diagnostics, Varian, and Advanced Therapies.

Shares of Siemens Healthineers AG (ETR:SHL - ) traded up 1.5% during trading on Monday . The stock traded as high as €39.46 and last traded at €38.91. 1,488,176 shares changed hands during mid-day trading, The stock had previously closed at €38.35.

Siemens Healthineers Price Performance

The stock has a market capitalization of $43.90 billion, a PE ratio of 22.62, a PEG ratio of 1.16 and a beta of 0.80. The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 82.28. The company's 50 day simple moving average is €38.96 and its 200 day simple moving average is €42.89.

Siemens Healthineers Company Profile

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.